Ewa Surmiak

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 23

Top Venues

Molecules (Basel, Switzerland)

ACS medicinal chemistry letters

RSC medicinal chemistry

Journal of medicinal chemistry

Jagiellonian University, Faculty of Chemistry

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Jagiellonian University, Faculty of Chemistry Oct 01 2015

Poland

PhD

Publications

Robin van der Straat, Rosalie Draijer, Ewa Surmiak, Roberto Butera, Lennart Land, Katarzyna Magiera-Mularz, Bogdan Musielak, Jacek Plewka, Tad A Holak, Alexander S S Dömling
1,5-Disubstituted tetrazoles as PD-1/PD-L1 antagonists. RSC medicinal chemistry 15 (4) (2024)
Atilio Reyes Romero, Katarzyna Kubica, Radoslaw Kitel, Ismael Rodriguez, Katarzyna Magiera-Mularz, Alexander Dömling, Tad A Holak, Ewa Surmiak
Correction: Reyes Romero et al. Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules 2022, 27 , 8282. Molecules (Basel, Switzerland) 29 (12) (2024)
Joanna Klimek, Oskar Kruc, Joanna Ceklarz, Beata Kaminska, Bogdan M Musielak, Robin van der Straat, Alexander S S Dömling, Tad A Holak, Damian Muszak, Justyna Kalinowska-Tluscik, Łukasz Skalniak, Ewa Surmiak
C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction. Molecules (Basel, Switzerland) 29 (11) (2024)
Joanna Klimek, Oskar Kruc, Joanna Ceklarz, Beata Kaminska, Bogdan M Musielak, Robin van der Straat, Alexander S S Dömling, Tad A Holak, Damian Muszak, Justyna Kalinowska-Tluscik, Łukasz Skalniak, Ewa Surmiak
C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction. Molecules (Basel, Switzerland) 29 (11) (2024)
Robin van der Straat, Rosalie Draijer, Ewa Surmiak, Roberto Butera, Lennart Land, Katarzyna Magiera-Mularz, Bogdan Musielak, Jacek Plewka, Tad A Holak, Alexander S S Dömling
1,5-Disubstituted tetrazoles as PD-1/PD-L1 antagonists. RSC medicinal chemistry 15 (4) (2024)
Joanna Klimek, Oskar Kruc, Joanna Ceklarz, Beata Kaminska, Bogdan M Musielak, Robin van der Straat, Alexander S S Dömling, Tad A Holak, Damian Muszak, Justyna Kalinowska-Tluscik, Łukasz Skalniak, Ewa Surmiak
C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction. Molecules (Basel, Switzerland) 29 (11) (2024)
Atilio Reyes Romero, Katarzyna Kubica, Radoslaw Kitel, Ismael Rodriguez, Katarzyna Magiera-Mularz, Alexander Dömling, Tad A Holak, Ewa Surmiak
Correction: Reyes Romero et al. Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules 2022, 27 , 8282. Molecules (Basel, Switzerland) 29 (12) (2024)
Ewa Surmiak, Julia Ząber, Jacek Plewka, Grzegorz Wojtanowicz, Justyna Kocik-Krol, Oskar Kruc, Damian Muszak, Ismael Rodriguez, Bogdan M Musielak, Monica Viviano, Sabrina Castellano, Łukasz Skalniak, Katarzyna Magiera-Mularz, Tad A Holak, Justyna Kalinowska-Tłuścik
Solubilizer Tag Effect on PD-L1/Inhibitor Binding Properties for m -Terphenyl Derivatives. ACS medicinal chemistry letters 15 (1) (2023)
Ewa Surmiak, Julia Ząber, Jacek Plewka, Grzegorz Wojtanowicz, Justyna Kocik-Krol, Oskar Kruc, Damian Muszak, Ismael Rodriguez, Bogdan M Musielak, Monica Viviano, Sabrina Castellano, Łukasz Skalniak, Katarzyna Magiera-Mularz, Tad A Holak, Justyna Kalinowska-Tłuścik
Solubilizer Tag Effect on PD-L1/Inhibitor Binding Properties for m -Terphenyl Derivatives. ACS medicinal chemistry letters 15 (1) (2023)
Radoslaw Kitel, Ewa Surmiak, Jan Borggräfe, Justyna Kalinowska-Tluscik, Przemyslaw Golik, Miroslawa Czub, Wiktor Uzar, Bogdan M Musielak, Mariusz Madej, Grzegorz M Popowicz, Grzegorz Dubin, Tad A Holak
Discovery of Inhibitory Fragments That Selectively Target Spire2-FMN2 Interaction. Journal of medicinal chemistry (2023)
Radoslaw Kitel, Ismael Rodriguez, Xabier Del Corte, Jack Atmaj, Magdalena Żarnik, Ewa Surmiak, Damian Muszak, Katarzyna Magiera-Mularz, Grzegorz M Popowicz, Tad A Holak, Bogdan M Musielak
Exploring the Surface of the Ectodomain of the PD-L1 Immune Checkpoint with Small-Molecule Fragments. ACS chemical biology 17 (9) (2022)
Atilio Reyes Romero, Katarzyna Kubica, Radoslaw Kitel, Ismael Rodriguez, Katarzyna Magiera-Mularz, Alexander Dömling, Tad A Holak, Ewa Surmiak
Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules (Basel, Switzerland) 27 (23) (2022)
Atilio Reyes Romero, Katarzyna Kubica, Radoslaw Kitel, Ismael Rodriguez, Katarzyna Magiera-Mularz, Alexander Dömling, Tad A Holak, Ewa Surmiak
Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules (Basel, Switzerland) 27 (23) (2022)
Atilio Reyes Romero, Katarzyna Kubica, Radoslaw Kitel, Ismael Rodriguez, Katarzyna Magiera-Mularz, Alexander Dömling, Tad A Holak, Ewa Surmiak
Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules (Basel, Switzerland) 27 (23) (2022)
Atilio Reyes Romero, Katarzyna Kubica, Radoslaw Kitel, Ismael Rodriguez, Katarzyna Magiera-Mularz, Alexander Dömling, Tad A Holak, Ewa Surmiak
Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules (Basel, Switzerland) 27 (23) (2022)
Shabnam Shaabani, Louis Gadina, Ewa Surmiak, Zefeng Wang, Bidong Zhang, Roberto Butera, Tryfon Zarganes-Tzitzikas, Ismael Rodriguez, Justyna Kocik-Krol, Katarzyna Magiera-Mularz, Łukasz Skalniak, Alexander S S Dömling, Tad A Holak
Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. Molecules (Basel, Switzerland) 27 (11) (2022)
Damian Muszak, Ewa Surmiak, Jacek Plewka, Katarzyna Magiera-Mularz, Justyna Kocik-Krol, Bogdan M Musielak, Dominik Sala, Radoslaw Kitel, Malgorzata Stec, Kazimierz Weglarczyk, Maciej Siedlar, Alexander S S Dömling, Łukasz Skalniak, Tad A Holak
Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction. Journal of medicinal chemistry 64 (15) (2021)
Roberto Butera, Marta Ważyńska, Katarzyna Magiera-Mularz, Jacek Plewka, Bogdan M Musielak, Ewa Surmiak, Dominik Sala, Radoslaw Kitel, Marco de Bruyn, Hans W Nijman, Philip H Elsinga, Tad A Holak, Alexander S S Dömling
Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists. ACS medicinal chemistry letters 12 (5) (2021)
Ewa Surmiak, Katarzyna Magiera-Mularz, Bogdan M Musielak, Damian Muszak, Justyna Kocik-Krol, Radoslaw Kitel, Jacek Plewka, Tad A Holak, Łukasz Skalniak
PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action. International journal of molecular sciences 22 (21) (2021)
Constantinos G Neochoritis, Maryam Kazemi Miraki, Eman M M Abdelraheem, Ewa Surmiak, Tryfon Zarganes-Tzitzikas, Beata Łabuzek, Tad A Holak, Alexander Dömling
Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists. Beilstein journal of organic chemistry 15 (2019)
Justyna Kocik-Krol, Monika Machula, Aneta Wisniewska, Ewa Surmiak, Tad A Holak, Łukasz Skalniak
Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists. Cancers 11 (7) (2019)
Łukasz Skalniak, Aleksandra Twarda-Clapa, Constantinos G Neochoritis, Ewa Surmiak, Monika Machula, Aneta Wisniewska, Beata Labuzek, Ameena M Ali, Sylwia Krzanik, Grzegorz Dubin, Matthew Groves, Alexander Dömling, Tad A Holak
A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells. The FEBS journal 286 (7) (2019)
Łukasz Skalniak, Ewa Surmiak, Tad A Holak
A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018). Expert opinion on therapeutic patents 29 (3) (2019)

Ewa Surmiak.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Ewa Surmiak